Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 198.57
ABAX's Cash to Debt is ranked higher than
82% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. ABAX: 198.57 )
ABAX' s 10-Year Cash to Debt Range
Min: 0.46   Max: No Debt
Current: 198.57

Equity to Asset 0.86
ABAX's Equity to Asset is ranked higher than
93% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. ABAX: 0.86 )
ABAX' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.9
Current: 0.86

0.48
0.9
F-Score: 4
Z-Score: 25.69
M-Score: -2.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.56
ABAX's Operating margin (%) is ranked higher than
91% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. ABAX: 14.56 )
ABAX' s 10-Year Operating margin (%) Range
Min: -930   Max: 22.65
Current: 14.56

-930
22.65
Net-margin (%) 9.27
ABAX's Net-margin (%) is ranked higher than
89% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. ABAX: 9.27 )
ABAX' s 10-Year Net-margin (%) Range
Min: -900   Max: 51.27
Current: 9.27

-900
51.27
ROE (%) 8.85
ABAX's ROE (%) is ranked higher than
81% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. ABAX: 8.85 )
ABAX' s 10-Year ROE (%) Range
Min: -61.71   Max: 62.55
Current: 8.85

-61.71
62.55
ROA (%) 7.77
ABAX's ROA (%) is ranked higher than
90% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. ABAX: 7.77 )
ABAX' s 10-Year ROA (%) Range
Min: -49.56   Max: 50.99
Current: 7.77

-49.56
50.99
ROC (Joel Greenblatt) (%) 35.45
ABAX's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. ABAX: 35.45 )
ABAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -154.55   Max: 57.43
Current: 35.45

-154.55
57.43
Revenue Growth (%) 6.60
ABAX's Revenue Growth (%) is ranked higher than
76% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. ABAX: 6.60 )
ABAX' s 10-Year Revenue Growth (%) Range
Min: 6.6   Max: 93.9
Current: 6.6

6.6
93.9
EBITDA Growth (%) 1.90
ABAX's EBITDA Growth (%) is ranked higher than
76% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ABAX: 1.90 )
ABAX' s 10-Year EBITDA Growth (%) Range
Min: -33.7   Max: 171.4
Current: 1.9

-33.7
171.4
EPS Growth (%) -0.50
ABAX's EPS Growth (%) is ranked higher than
76% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. ABAX: -0.50 )
ABAX' s 10-Year EPS Growth (%) Range
Min: -59.2   Max: 159.6
Current: -0.5

-59.2
159.6
» ABAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ABAX Guru Trades in Q4 2013

PRIMECAP Management 575,000 sh (New)
Joel Greenblatt 25,721 sh (New)
Jim Simons 100,869 sh (+165.65%)
Chuck Royce Sold Out
» More
Q1 2014

ABAX Guru Trades in Q1 2014

PRIMECAP Management 1,979,300 sh (+244.23%)
Jim Simons Sold Out
Joel Greenblatt 20,229 sh (-21.35%)
» More
Q2 2014

ABAX Guru Trades in Q2 2014

Joel Greenblatt 26,303 sh (+30.03%)
PRIMECAP Management 1,975,700 sh (-0.18%)
» More
Q3 2014

ABAX Guru Trades in Q3 2014

Columbia Wanger 602,000 sh (New)
Jim Simons 7,600 sh (New)
PRIMECAP Management 1,973,200 sh (-0.13%)
Joel Greenblatt 16,012 sh (-39.12%)
» More
» Details

Insider Trades

Latest Guru Trades with ABAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Reduce -39.12%0.01%$41.8 - $53.11 $ 59.7327%16012
Joel Greenblatt 2014-06-30 Add 30.03%$37.95 - $44.61 $ 59.7344%26303
PRIMECAP Management 2014-03-31 Add 244.23%0.06%$36.29 - $45.01 $ 59.7350%1979300
Joel Greenblatt 2014-03-31 Reduce -21.35%0.01%$36.29 - $45.01 $ 59.7350%20229
PRIMECAP Management 2013-12-31 New Buy0.03%$32.4 - $41.25 $ 59.7362%575000
Joel Greenblatt 2013-12-31 New Buy0.02%$32.4 - $41.25 $ 59.7362%25721
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 78.70
ABAX's P/E(ttm) is ranked higher than
78% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 78.70 )
ABAX' s 10-Year P/E(ttm) Range
Min: 10.19   Max: 113.81
Current: 78.7

10.19
113.81
P/B 6.60
ABAX's P/B is ranked higher than
64% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. ABAX: 6.60 )
ABAX' s 10-Year P/B Range
Min: 2.19   Max: 12.21
Current: 6.6

2.19
12.21
P/S 7.30
ABAX's P/S is ranked higher than
64% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.06 vs. ABAX: 7.30 )
ABAX' s 10-Year P/S Range
Min: 2.48   Max: 9.5
Current: 7.3

2.48
9.5
PFCF 43.20
ABAX's PFCF is ranked higher than
83% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 43.20 )
ABAX' s 10-Year PFCF Range
Min: 21.92   Max: 101.52
Current: 43.2

21.92
101.52
EV-to-EBIT 44.67
ABAX's EV-to-EBIT is ranked higher than
77% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 44.67 )
ABAX' s 10-Year EV-to-EBIT Range
Min: 10.6   Max: 103.6
Current: 44.67

10.6
103.6
PEG 9.28
ABAX's PEG is ranked higher than
88% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 9.28 )
ABAX' s 10-Year PEG Range
Min: 0.19   Max: 13.47
Current: 9.28

0.19
13.47
Shiller P/E 78.30
ABAX's Shiller P/E is ranked higher than
86% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 78.30 )
ABAX' s 10-Year Shiller P/E Range
Min: 21.13   Max: 317.57
Current: 78.3

21.13
317.57
Current Ratio 6.53
ABAX's Current Ratio is ranked higher than
90% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. ABAX: 6.53 )
ABAX' s 10-Year Current Ratio Range
Min: 1.54   Max: 9.82
Current: 6.53

1.54
9.82
Quick Ratio 5.48
ABAX's Quick Ratio is ranked higher than
90% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. ABAX: 5.48 )
ABAX' s 10-Year Quick Ratio Range
Min: 1.12   Max: 8.45
Current: 5.48

1.12
8.45

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.50
ABAX's Dividend Yield is ranked lower than
82% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.31 vs. ABAX: 0.50 )
ABAX' s 10-Year Dividend Yield Range
Min: 0.21   Max: 0.42
Current: 0.5

0.21
0.42
Dividend Payout 0.26
ABAX's Dividend Payout is ranked higher than
92% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 0.26 )
ABAX' s 10-Year Dividend Payout Range
Min: 0.42   Max: 0.48
Current: 0.26

0.42
0.48
Yield on cost (5-Year) 0.50
ABAX's Yield on cost (5-Year) is ranked lower than
81% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. ABAX: 0.50 )
ABAX' s 10-Year Yield on cost (5-Year) Range
Min: 0.21   Max: 0.42
Current: 0.5

0.21
0.42
Share Buyback Rate 0.40
ABAX's Share Buyback Rate is ranked higher than
90% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.60 vs. ABAX: 0.40 )
ABAX' s 10-Year Share Buyback Rate Range
Min: 0.4   Max: -18
Current: 0.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.70
ABAX's Price/Net Cash is ranked higher than
87% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 18.70 )
ABAX' s 10-Year Price/Net Cash Range
Min: 5.92   Max: 300
Current: 18.7

5.92
300
Price/Net Current Asset Value 11.80
ABAX's Price/Net Current Asset Value is ranked higher than
85% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 11.80 )
ABAX' s 10-Year Price/Net Current Asset Value Range
Min: 4.17   Max: 287.5
Current: 11.8

4.17
287.5
Price/Tangible Book 6.70
ABAX's Price/Tangible Book is ranked higher than
74% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.74 vs. ABAX: 6.70 )
ABAX' s 10-Year Price/Tangible Book Range
Min: 2.17   Max: 36.9
Current: 6.7

2.17
36.9
Price/DCF (Projected) 3.30
ABAX's Price/DCF (Projected) is ranked higher than
84% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 3.30 )
ABAX' s 10-Year Price/DCF (Projected) Range
Min: 1.7   Max: 180.9
Current: 3.3

1.7
180.9
Price/Median PS Value 1.50
ABAX's Price/Median PS Value is ranked higher than
68% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. ABAX: 1.50 )
ABAX' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 8.88
Current: 1.5

0.31
8.88
Price/Peter Lynch Fair Value 8.00
ABAX's Price/Peter Lynch Fair Value is ranked higher than
89% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 8.00 )
ABAX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.52   Max: 11.31
Current: 8

0.52
11.31
Price/Graham Number 4.80
ABAX's Price/Graham Number is ranked higher than
84% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ABAX: 4.80 )
ABAX' s 10-Year Price/Graham Number Range
Min: 1.42   Max: 10.96
Current: 4.8

1.42
10.96
Earnings Yield (Greenblatt) 2.20
ABAX's Earnings Yield (Greenblatt) is ranked higher than
76% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. ABAX: 2.20 )
ABAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 9.5
Current: 2.2

1
9.5
Forward Rate of Return (Yacktman) 11.33
ABAX's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.35 vs. ABAX: 11.33 )
ABAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.4   Max: 55.9
Current: 11.33

-0.4
55.9

Analyst Estimate

Mar15 Mar16 Mar17
Revenue(Mil) 207 243 273
EPS($) 0.98 1.27 1.42
EPS without NRI($) 0.98 1.27 1.42

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AXS.Germany,
Abaxis Inc is a California corporation and was incorporated in 1989. The Company is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. Its products and services include point-of-care diagnostic instruments and consumables used in the medical market, point-of-care diagnostic instruments and consumables used in the veterinary market, and veterinary reference laboratory diagnostic and consulting services for veterinarians provided by Abaxis Veterinary Reference Laboratories (AVRL). The Company manages its business in two reportable business segments, the medical market and the veterinary market, which are based on the diagnostic products sold and services provided by market and customer group. For products that it sells that are not specifically identified to any particular business segment, it categorizes the revenue as Other. The Companys products sold to the medical market are used by medical specialties requiring real time results to enable rapid clinical decisions in the area of human diagnostics. Its point-of-care products in the medical market are comprised of its Piccolo chemistry analyzers and consumable products. In the veterinary market, its VetScan products serves a customer group consisting of companion animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies and private research laboratories. Its product and service offerings in the veterinary market include VetScan Point-of-Care Blood Chemistry Instruments, VetScan Profiles, Hematology Instruments and Consumables, VSpro Specialty Analyzers and Consumables, i-STAT Instruments and Consumables, Rapid Tests, and Abaxis Veterinary Reference Laboratories services. Its Other segment include sale of products using its patented Orbos Discrete Lyophilization Process (the Orbos process) to companies for other applications. The Orbos process involves flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The Orbos beads are stable in dry form and dissolve rapidly in aqueous solutions. The dry reagents used in its reagent discs are produced using the Orbos process. This process allows the production of a precise amount of active chemical ingredient in the form of a soluble bead. The Company markets and sells its products worldwide by maintaining direct sales forces and through independent distributors. It competes with Alere, Alfa Wassermann S.P.A., Johnson & Johnson (including its subsidiary, Ortho-Clinical Diagnostics, Inc.), F. Hoffmann-La Roche Ltd, Idexx Laboratories, Inc. and Heska Corporation. The Companys Piccolo products are in vitro diagnostic medical devices subj
» More Articles for ABAX

Headlines

Articles On GuruFocus.com
ABAXIS Inc. (ABAX) COO Donald Peter Wood sells 6,460 Shares Mar 08 2011 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 35,000 Shares Dec 10 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 96,000 Shares Dec 08 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 66,029 Shares Dec 07 2010 
ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. Jan 13 2009 


More From Other Websites
TG Therapeutics, Inc. (TGTX) in Focus: Stock Soars 21.2% Dec 12 2014
Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2014 Animal & Dental Summit Dec 05 2014
Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2014 Animal & Dental Summit Dec 05 2014
Is Abaxis (ABAX) Worth Adding to Your Investment Portfolio? Nov 26 2014
Abaxis, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 25 2014
Abaxis, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 25 2014
Abaxis Plans Direct Market Approach, Buys Distributor in UK Nov 24 2014
Abaxis Acquires UK-based Distribution Organization Nov 21 2014
Abaxis Acquires UK-based Distribution Organization Nov 21 2014
3 Innovative Names To Watch In Medical Technology Nov 19 2014
ABAXIS INC Financials Nov 19 2014
Enzymotec Ltd. (ENZY) in Focus: Stock Rallies 15% Nov 18 2014
Abaxis, Inc. to Present at the Canaccord Genuity Medical Technology & Diagnostic Forum Nov 14 2014
Abaxis, Inc. to Present at the Canaccord Genuity Medical Technology & Diagnostic Forum Nov 14 2014
10-Q for ABAXIS, Inc. Nov 12 2014
Abaxis, Inc. to Present at the Stifel 2014 Healthcare Conference Nov 12 2014
Abaxis, Inc. to Present at the Stifel 2014 Healthcare Conference Nov 12 2014
INSYS Therapeutics (INSY) in Focus: Stock Rises 12% Nov 12 2014
ABAXIS INC Files SEC form 10-Q, Quarterly Report Nov 10 2014
Abaxis (ABAX) Shares March Higher, Can It Continue? Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK